260 related articles for article (PubMed ID: 27546885)
1. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Ma H; Vogl FD; Bach BA; Oza AM
Gynecol Oncol; 2016 Oct; 143(1):27-34. PubMed ID: 27546885
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Monk BJ; Poveda A; Vergote I; Raspagliesi F; Fujiwara K; Bae DS; Oaknin A; Ray-Coquard I; Provencher DM; Karlan BY; Lhommé C; Richardson G; Rincón DG; Coleman RL; Herzog TJ; Marth C; Brize A; Fabbro M; Redondo A; Bamias A; Tassoudji M; Navale L; Warner DJ; Oza AM
Lancet Oncol; 2014 Jul; 15(8):799-808. PubMed ID: 24950985
[TBL] [Abstract][Full Text] [Related]
3. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
[TBL] [Abstract][Full Text] [Related]
4. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Fujiwara K; Monk BJ; Lhommé C; Coleman RL; Brize A; Oaknin A; Ray-Coquard I; Fabbro M; Provencher D; Bamias A; Vergote I; DeCensi A; Zhang K; Vogl FD; Bach BA; Raspagliesi F
Ann Oncol; 2016 Jun; 27(6):1006-1013. PubMed ID: 27029706
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Karlan BY; Oza AM; Richardson GE; Provencher DM; Hansen VL; Buck M; Chambers SK; Ghatage P; Pippitt CH; Brown JV; Covens A; Nagarkar RV; Davy M; Leath CA; Nguyen H; Stepan DE; Weinreich DM; Tassoudji M; Sun YN; Vergote IB
J Clin Oncol; 2012 Feb; 30(4):362-71. PubMed ID: 22184370
[TBL] [Abstract][Full Text] [Related]
7. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
10. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.
Reardon DA; Lassman AB; Schiff D; Yunus SA; Gerstner ER; Cloughesy TF; Lee EQ; Gaffey SC; Barrs J; Bruno J; Muzikansky A; Duda DG; Jain RK; Wen PY
Cancer; 2018 Apr; 124(7):1438-1448. PubMed ID: 29266174
[TBL] [Abstract][Full Text] [Related]
15. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Lee EQ; Zhang P; Wen PY; Gerstner ER; Reardon DA; Aldape KD; deGroot JF; Pan E; Raizer JJ; Kim LJ; Chmura SJ; Robins HI; Connelly JM; Battiste JD; Villano JL; Wagle N; Merrell RT; Wendland MM; Mehta MP
Cancer; 2020 Jun; 126(12):2821-2828. PubMed ID: 32154928
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR; Wu B; Agarwal N; Bowles DW; Lam ET; Werner TL; Rasmussen E; Gamelin E; Soto F; Friberg G; Sun YN; Sharma S
Invest New Drugs; 2015 Jun; 33(3):691-9. PubMed ID: 25895965
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.
Vergote I; Oaknin A; Baurain JF; Ananda S; Wong S; Su X; Wu B; Zhong Z; Warner D; Casado A
Eur J Cancer; 2014 Sep; 50(14):2408-16. PubMed ID: 25037684
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
[TBL] [Abstract][Full Text] [Related]
20. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.
Kaufman PA; Wildiers H; Freyer G; Kemeny M; Gonçalves A; Jerusalem G; Stopeck A; Vrindavanam N; Dalenc F; Nanayakkara N; Wu B; Pickett CA
Clin Breast Cancer; 2019 Feb; 19(1):47-57. PubMed ID: 30420181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
